Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Account Payables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Change in Account Payables for 8 consecutive years, with $220000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 218.28% to $220000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $385000.0, a 333.33% increase, with the full-year FY2024 number at -$2.1 million, down 238.99% from a year prior.
  • Change in Account Payables was $220000.0 for Q3 2025 at Precision Biosciences, up from $199000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.0 million in Q4 2023 to a low of -$2.1 million in Q1 2024.
  • A 5-year average of $39210.5 and a median of $72000.0 in 2024 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 708.33% in 2022; the steepest drop was 593.1% in 2022.
  • Precision Biosciences' Change in Account Payables stood at $627000.0 in 2021, then plummeted by 45.77% to $340000.0 in 2022, then soared by 489.12% to $2.0 million in 2023, then crashed by 96.41% to $72000.0 in 2024, then soared by 205.56% to $220000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Change in Account Payables are $220000.0 (Q3 2025), $199000.0 (Q2 2025), and -$106000.0 (Q1 2025).